Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial

Califf, RM; Boolell, M; Haffner, SM; Bethel, MA; McMurray, J; Duggal, A; Holman, RR; NAVIGATOR, ; Study Group, (2008). Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. American Heart Journal, 156(4), (2008), pp. 623-632. St. Louis, Mo.: Elsevier 10.1016/j.ahj.2008.05.017

Full text not available from this repository.

Item Type:	Journal Article (Original Article)
Division/Institute:	04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Endocrinology, Diabetology and Clinical Nutrition
UniBE Contributor:	Diem, Peter
ISSN:	0002-8703
Publisher:	Elsevier
Language:	English
Submitter:	Factscience Import
Date Deposited:	04 Oct 2013 15:06
Last Modified:	05 Dec 2022 14:20
Publisher DOI:	10.1016/j.ahj.2008.05.017
Web of Science ID:	000259963300002
URI:	https://boris.unibe.ch/id/eprint/28735 (FactScience: 128358)